This playbook explores the need for innovative solutions to keep up with the demand for sterile drug products, and how partnering with a CDMO can help.
Sterile drug development is experiencing rapid growth as pharma manufacturers turn their focus to orphan drugs, mRNA therapies and repurposed drugs. As these innovations continue to become more common, it creates an increased demand for sterile manufacturing operations. Outsourcing sterile drug development to contract development manufacturing organizations (CDMOs) can help boost capacity and an experienced pharmaceutical development services (PDS) team provides end-to-end support in the process.
This playbook explores the need for innovative solutions to keep up with the demand for sterile drug products, and how partnering with a CDMO with an experienced PDS team to support sterile manufacturing can help pharma companies avoid rework and costly delays. It will cover the distinct advantages CDMOs provide pharma companies to help overcome challenges that can hinder sterile drug development, including:
- Advanced technologies
- Reduced investments
- Faster product entrance to market
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Thermo Fisher Scientific
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Thermo Fisher Scientific
